List of Tables
Table 1. Benign Prostatic Hyperplasia Therapeutics Market Trends
Table 2. Benign Prostatic Hyperplasia Therapeutics Market Drivers & Opportunity
Table 3. Benign Prostatic Hyperplasia Therapeutics Market Challenges
Table 4. Benign Prostatic Hyperplasia Therapeutics Market Restraints
Table 5. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Benign Prostatic Hyperplasia Therapeutics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Benign Prostatic Hyperplasia Therapeutics Product Type
Table 9. Key Companies Time to Begin Mass Production of Benign Prostatic Hyperplasia Therapeutics
Table 10. Global Benign Prostatic Hyperplasia Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Region (2019-2024) & (%)
Table 27. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Benign Prostatic Hyperplasia Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Benign Prostatic Hyperplasia Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Benign Prostatic Hyperplasia Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 31. Abbott Laboratories Basic Information List
Table 32. Abbott Laboratories Description and Business Overview
Table 33. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of Abbott Laboratories (2019-2024)
Table 35. Abbott Laboratories Recent Developments
Table 36. Allergan plc Basic Information List
Table 37. Allergan plc Description and Business Overview
Table 38. Allergan plc Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of Allergan plc (2019-2024)
Table 40. Allergan plc Recent Developments
Table 41. Astellas Pharma Basic Information List
Table 42. Astellas Pharma Description and Business Overview
Table 43. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of Astellas Pharma (2019-2024)
Table 45. Astellas Pharma Recent Developments
Table 46. Boehringer Ingelheim Pharma GmbH and Co. KG Basic Information List
Table 47. Boehringer Ingelheim Pharma GmbH and Co. KG Description and Business Overview
Table 48. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of Boehringer Ingelheim Pharma GmbH and Co. KG (2019-2024)
Table 50. Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments
Table 51. Eli Lilly and Company Basic Information List
Table 52. Eli Lilly and Company Description and Business Overview
Table 53. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of Eli Lilly and Company (2019-2024)
Table 55. Eli Lilly and Company Recent Developments
Table 56. GlaxoSmithKline plc Basic Information List
Table 57. GlaxoSmithKline plc Description and Business Overview
Table 58. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 59. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of GlaxoSmithKline plc (2019-2024)
Table 60. GlaxoSmithKline plc Recent Developments
Table 61. Merck and Co. Basic Information List
Table 62. Merck and Co. Description and Business Overview
Table 63. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 64. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of Merck and Co. (2019-2024)
Table 65. Merck and Co. Recent Developments
Table 66. Pfizer Basic Information List
Table 67. Pfizer Description and Business Overview
Table 68. Pfizer Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 69. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of Pfizer (2019-2024)
Table 70. Pfizer Recent Developments
Table 71. Sanofi Basic Information List
Table 72. Sanofi Description and Business Overview
Table 73. Sanofi Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 74. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of Sanofi (2019-2024)
Table 75. Sanofi Recent Developments
Table 76. Teva Pharmaceutical Industries Limited Basic Information List
Table 77. Teva Pharmaceutical Industries Limited Description and Business Overview
Table 78. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Products, Services and Solutions
Table 79. Revenue (US$ Million) in Benign Prostatic Hyperplasia Therapeutics Business of Teva Pharmaceutical Industries Limited (2019-2024)
Table 80. Teva Pharmaceutical Industries Limited Recent Developments
Table 81. Key Raw Materials Lists
Table 82. Raw Materials Key Suppliers Lists
Table 83. Benign Prostatic Hyperplasia Therapeutics Downstream Customers
Table 84. Benign Prostatic Hyperplasia Therapeutics Distributors List
Table 85. Research Programs/Design for This Report
Table 86. Key Data Information from Secondary Sources
Table 87. Key Data Information from Primary Sources
Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Benign Prostatic Hyperplasia Therapeutics Product Picture
Figure 2. Global Benign Prostatic Hyperplasia Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Benign Prostatic Hyperplasia Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Benign Prostatic Hyperplasia Therapeutics Report Years Considered
Figure 5. Global Benign Prostatic Hyperplasia Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Benign Prostatic Hyperplasia Therapeutics Revenue in 2023
Figure 7. Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Alpha Blocker Picture
Figure 9. 5-Alpha Reductase Inhibitor Picture
Figure 10. Phosphodiesterase-5 Inhibitor Picture
Figure 11. Others Picture
Figure 12. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Benign Prostatic Hyperplasia Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Mono Drug Therapy
Figure 15. Product Picture of Combination Drug Therapy
Figure 16. Global Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 17. Global Benign Prostatic Hyperplasia Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 18. North America Benign Prostatic Hyperplasia Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 19. North America Benign Prostatic Hyperplasia Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 20. Europe Benign Prostatic Hyperplasia Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 21. Europe Benign Prostatic Hyperplasia Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 22. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 23. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 24. South America Benign Prostatic Hyperplasia Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 25. South America Benign Prostatic Hyperplasia Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 26. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 27. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 28. Key Countries/Regions Benign Prostatic Hyperplasia Therapeutics Sales Value (%), (2019-2030)
Figure 29. United States Benign Prostatic Hyperplasia Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 30. United States Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 31. United States Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 32. Europe Benign Prostatic Hyperplasia Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 33. Europe Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 34. Europe Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 35. China Benign Prostatic Hyperplasia Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 36. China Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 37. China Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 38. Japan Benign Prostatic Hyperplasia Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 39. Japan Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 40. Japan Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 41. South Korea Benign Prostatic Hyperplasia Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 42. South Korea Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 43. South Korea Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 44. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 46. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 47. India Benign Prostatic Hyperplasia Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 48. India Benign Prostatic Hyperplasia Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 49. India Benign Prostatic Hyperplasia Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 50. Benign Prostatic Hyperplasia Therapeutics Industrial Chain
Figure 51. Benign Prostatic Hyperplasia Therapeutics Manufacturing Cost Structure
Figure 52. Channels of Distribution (Direct Sales, and Distribution)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
